Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07210671

Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous

Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens

Amiens, 80480, France

Location status: Recruiting

Location contact

Laurent Bertoletti, MD

PRINCIPAL_INVESTIGATOR

Lina Khider, MD

PRINCIPAL_INVESTIGATOR

SOUDET Simon, MD

CONTACT

[email protected]

03 22 88 72 89

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18
  • Patient affiliated to a social security scheme
  • Patient who understands French
  • Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
  • Patient with active cancer:
  • Cancer treatment within the last 6 months,
  • Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
  • The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
  • Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

Exclusion criteria

  • Patients under legal protection
  • Patients with concomitant pulmonary embolism
  • Patient with proximal or distal deep vein thrombosis
  • Patient treated with anticoagulant therapy for another indication
  • Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
  • Patient opposed to participation in research

Treatment and study plan

Primary outcomes

  1. risk (in %) of recurrence of VTE

    Time frame: at 3-month follow-up

    risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.

Secondary outcomes

  1. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 3 months

  2. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 6 months

  3. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 12 months

  4. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 12 months

  5. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 3 months

  6. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 3 months

  7. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 6 months

  8. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 12 months

  9. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 6 months

  10. association (%) between initial treatment and bleeding events

    Time frame: at 6 months

  11. association (%) between initial treatment and bleeding events

    Time frame: at 3 months

  12. association (%) between initial treatment and bleeding events

    Time frame: at 12 months

  13. association(%) between initial treatment and all-cause death

    Time frame: at 3 months

  14. association(%) between initial treatment and all-cause death

    Time frame: at 6 months

  15. association(%) between initial treatment and all-cause death

    Time frame: at 12 months

  16. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 3 months

  17. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 6 months

  18. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 12 months

  19. rate of confirmed cancer in patients with TVS suspected of having cancer.

    Time frame: at 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Simon SOUDET, Dr

CONTACT

[email protected]

33+3 22 08 80 51

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: SUPERCAT

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Oct 7, 2025
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.